Clinical Trials in North Carolina

Showing 7801-7820 of 20,428 trials

A Study of Mirikizumab in Participants With Plaque Psoriasis

NCT03718884

This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab. The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.

Psoriasis

Eli Lilly and Company29 participantsStarted Oct 2018

Anaheim, California, United States • DeLand, Florida, United States • High Point, North Carolina, United States

COMPLETEDPhase 1/257 miles

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

NCT04125732

The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis (revascularization).

Coronary Artery DiseaseIschemiaAngina Refractory+2 more

XyloCor Therapeutics, Inc.41 participantsStarted Jan 2020

Stanford, California, United States • Washington D.C., District of Columbia, United States • Daytona Beach, Florida, United States +13 more locations

A Study of Mirikizumab in Participants With Plaque Psoriasis

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

Find Trials by Condition in North Carolina

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

EPI-743 for Mitochondrial Respiratory Chain Diseases

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

Incorporating Supersaturated Oxygen in Shock

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis